220 related articles for article (PubMed ID: 11915742)
41. Bullous variant of acral erythema in a child after high-dose methotrexate.
Zils K; Wilhelm M; Reeh T; Bielack S
Pediatr Hematol Oncol; 2012 May; 29(4):378-9. PubMed ID: 22568802
[No Abstract] [Full Text] [Related]
42. Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: a retrospective study.
Thiele OC; Freier K; Bacon C; Egerer G; Hofele CM
Br J Oral Maxillofac Surg; 2008 Oct; 46(7):533-6. PubMed ID: 18436357
[TBL] [Abstract][Full Text] [Related]
43. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
44. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
[TBL] [Abstract][Full Text] [Related]
45. High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.
Jaffe N; Gorlick R
J Clin Oncol; 2008 Sep; 26(27):4365-6. PubMed ID: 18802144
[No Abstract] [Full Text] [Related]
46. Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.
Mir O; Ropert S; Goldwasser F
Lancet Oncol; 2008 Dec; 9(12):1198. PubMed ID: 19038767
[No Abstract] [Full Text] [Related]
47. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate-induced bullous acral erythema in a child.
Werchniak AE; Chaffee S; Dinulos JG
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S93-5. PubMed ID: 15858519
[TBL] [Abstract][Full Text] [Related]
49. Reduced methotrexate clearance and renal impairment in a boy with osteosarcoma and earlier undetected autosomal dominant polycystic kidney disease (ADPKD).
Alberer M; Hoefele J; Bergmann C; Hartrampf S; Hilberath J; Pawlita I; Albert MH; Benz MR; Weber LT; Schmid I
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e314-6. PubMed ID: 20921908
[TBL] [Abstract][Full Text] [Related]
50. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
Pongracz N; Kelaridis T; Ritschl P
Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
[TBL] [Abstract][Full Text] [Related]
51. High-dose methotrexate is effective in osteosarcoma so what is the problem?
Cohen IJ
J Pediatr Hematol Oncol; 2009 Dec; 31(12):892-4. PubMed ID: 19887958
[No Abstract] [Full Text] [Related]
52. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
53. Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Robert G; Chappé C; Taque S; Bruneau B; Gandemer V
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e100-2. PubMed ID: 24309600
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
[TBL] [Abstract][Full Text] [Related]
55. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
56. [Transient cerebral dysfunction induced by VCR, HD-MTX in a child with acute lymphocytic leukemia].
Sato J; Yuasa Y; Tanaka H; Ninomiya T; Hirose M; Miyao M
Rinsho Ketsueki; 1986 Nov; 27(11):2162-7. PubMed ID: 3469437
[No Abstract] [Full Text] [Related]
57. [Neoadjuvant chemotherapy for osteosarcoma].
Guo W; Yang RL; Tang XD; Tang S; Li DS; Yang Y
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1186-90. PubMed ID: 15387981
[TBL] [Abstract][Full Text] [Related]
58. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
Goorin AM; Schwartzentruber DJ; Devidas M; Gebhardt MC; Ayala AG; Harris MB; Helman LJ; Grier HE; Link MP;
J Clin Oncol; 2003 Apr; 21(8):1574-80. PubMed ID: 12697883
[TBL] [Abstract][Full Text] [Related]
59. [Effect of high and low doses of methotrexate (MTX) on bone mass in subjects treated for osteosarcoma of the limbs].
Ripamonti C; Avella M; Gnudi S; Figus E
Minerva Med; 1993 Mar; 84(3):131-4. PubMed ID: 8492965
[TBL] [Abstract][Full Text] [Related]
60. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.
Eichler AF; Batchelor TT; Henson JW
Neuro Oncol; 2007 Jul; 9(3):373-7. PubMed ID: 17522329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
